Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Launched by NOVARTIS VACCINES · Dec 22, 2009
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Currently pregnant OR was pregnant following the introduction of the Novartis Pandemic Influenza A (H1N1) vaccine in the country of interest and have already experienced a pregnancy outcome
- • Consents to participate in the study
- Exclusion Criteria:
- • Is not currently pregnant OR was not pregnant at the time of or after the introduction of the Novartis Pandemic Influenza A (H1N1) vaccine in the country of interest
- • Does not consent to participate in the study
- • Has received a non-Novartis pandemic influenza vaccinee
About Novartis Vaccines
Novartis Vaccines, a division of Novartis, is dedicated to the research, development, and commercialization of innovative vaccines aimed at preventing infectious diseases and addressing unmet medical needs globally. With a strong focus on scientific excellence and patient safety, Novartis Vaccines leverages advanced technologies and collaborative partnerships to enhance vaccine efficacy and accessibility. The division is committed to advancing public health through rigorous clinical trials and is driven by a mission to protect lives and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, , Italy
Vicenza, , Italy
Udine, , Italy
Como, , Italy
Siena, , Italy
Rome, , Italy
Prato, , Italy
Monza, , Italy
Trieste, , Italy
Buenos Aires, , Argentina
Cordoba, , Argentina
Villa Nueva De Guaymallen, , Argentina
Bari, , Italy
Cagliari, , Italy
Milano, , Italy
Ilsselstein, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials